# Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.

Source: https://onco.cc/trials/nct07608159/  
OnCo record `nct07608159` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.

## Summary

Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. is a phase 3, randomised interventional study registered as NCT07608159 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 201 participants, started 2026-05 and due to reach its primary completion in 2029-05. Interventions recorded: Stereotactic body radiotherapy (SBRT); neoadjuvant immunotherapy; Neoadjuvant Chemotherapy. Conditions listed: Non Small Cell Lung Cancer; Stereotactic Body Radiotherapy; Neoadjuvant Chemoimmunotherapy; Surgery. Primary outcome: 2-year event-free survival rate. Lung eligibility wording from the registry: "* Previously untreated, pathologically confirmed, resectable or potentially -resectable stage II, IIIA, or IIIB (N2) non-small cell lung cancer according to the 8th edition of the American Joint Committee on Cancer staging system;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07608159
- Phase: 3
- Setting: A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatially Fractionated Stereotactic Body Radiotherapy Plus Toripalimab and Chemotherapy Versus Toripalimab Plus Chemotherapy in Patients With Resectable or Potentially Resectable Stage II-III Non-Small Cell Lung Cancer
- Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- Enrolled: 201

## Sources

- ClinicalTrials.gov NCT07608159: https://clinicaltrials.gov/study/NCT07608159

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07608159.json